The clinically satisfactory response rate for the 29 courses of therapy was 52%: critically ill, 44%; seriously ill, 50%; moderately ill, 80%. The response rates for various sites of infection were bone and cartilage, 100%; urinary tract infection, 56%; wound, 50%; respiratory tract, 67%; septicemia, 40%; abscess, 0%; burns, 44%. No adverse reactions were seen. Serum concentration (,g/ml ± standard deviation) of tobramycin determined by an agar-well plate method, were 4.81 4 2.17 (1 h); 3.24 + 1.43 (2 h); 2.35 i 1.30 (4 h); and 1.40 i 1.09 (8 h ). Tobramycin appears to be as effacacious -as gentamicin in the treatment of serious P. aeruginosa infections and has a theoretical advantage of lower minimal inhibitory concentration for P. aeruginosa. The data suggest that, for life-threatening infections, dosages of tobramycin may need to be increased over those used in this study.
Serious infections due to Pseudomonas aeruginosa have become increasingly frequent in recent years. Two factors responsible for this rise are the increasing numbers of immunologically compromised patients, and the frequent use of potent antibiotics which suppress or eliminate sensitive bacteria, thus favoring the growth of Pseudomonas (12) . Gentamicin and carbenicillin have been the most effective antibiotics for Pseudomonas infections but strains resistant to one or both have emerged (6) . Tobramycin, an aminoglycoside chemically similar to gentamicin, has been shown to possess a greater in vitro effectiveness against P. aeruginosa. For most strains of Pseudomonas, the minimal inhibitory concentrations (MIC) of tobramycin frequently have been slightly less than that of gentamicin (2, 3, 11, 13, 19) . However, few data on the clinical efficacy of tobramycin have yet been published (8, 9) . We have investigated the efficacy of tobramycin in 25 hospitalized patients with serious infections caused by P. aeruginosa.
MATERIALS AND METHODS
After informed consent was obtained, tobramycin at a dose of 2.7 to 5.6 mg/kg per day was administered to 25 University of Michigan Medical Center hospitalized patients between April 1972 and September 1973. Loading doses were not administered. P. aeruginosa had been isolated from each patient admitted to the study and was considered the primary pathogen in each case. All bacteria were cultured and identified in the Clinical Microbiology Laboratory using standard techniques. Tobramycin and gentamicin disk diffusion sensitivities were performed by the Bauer-Kirby technique using 10-lAg disks (1) . MIC and bactericidal (MBC) concentrations of tobramycin and gentamicin were determined in the research laboratories of the Infectious Disease Division by microtiter methods using twofold dilutions in Mueller-Hinton broth (6, 7) .
Fifteen of the 25 patients (60%) were moribund on admission to the study and were classified as critically ill. Five more were seriously ill, but were not thought to be moribund initially; five were moderately ill. 20  23  19  14  17  23  19  22  19  22  21  18  19  24  22  20  20  19  18  18  20  14  14  14  15  18  20  22  16  15  14  20  16  18  18  18  21  15  18  18  16 For 80% (46/57) of the strains, the tobramycin MIC was less than the gentamicin MIC: seven strains showed differences of three tube dilutions; 20 showed two tube dilution differences; and 19 showed a one tube dilution difference. For eight strains the MIC with both antibiotics were identical, and only three strains were more susceptible to gentamicin (5.3%).
Similarly, 74% of the gentamicin MBC were greater than the corresponding tobramycin MBC (42/57: 12, three tube; 17, two tube; 13, one tube). For eight strains the MBC of both antibiotics was the same, whereas for seven strains gentamicin had a lower MBC. The correlation between tobramycin and gentamicin MIC and MBC is shown in Fig. 1 and 2, which demonstrate the significant difference in favor of tobramycin.
All Pseudomonas strains had an MIC of 1.6
Ag/ml or less with tobramycin, whereas 10.5% of the strains had an MIC greater than 1.6 ,ug/ml with gentamicin. Pharmacokinetics. Serum samples were obtained from 20 of the 25 patients, 13 of whom received tobramycin intramuscularly. After intramuscular injection (1.14 i 0.22 mg/kg; mean i standard deviation) the peak mean serum level obtained (at 1 h) was 4.81 i 2.17 ,g/ml with 2-, 4-and 8-h levels of 3.24 + 1.43, 2.35 i 1.30, and 1.40 i 1.09 (Fig. 3) . Assay of serum tobramycin levels from patients receiving the drug intravenously was precluded in our bioassay because of the concomitant administration of antibiotics such as clindamycin, tetracycline, or chloramphenicol.
After intramuscular injection of 1.1 mg/kg, serum tobramycin disappearance half-times of 33.0, 33.5, and 50.0 h were found in an azotemic patient (no. 6) who was undergoing intermittent hemodialysis for post-traumatic acute tubular necrosis. Doses of 1.3 mg/kg gave peak serum levels of 12 to 13 Ag/ml in this patient; 8. The results may also be examined by classifying the courses of treatment by disease entity ( Table 2) , or by antibiotic treatment (Table 3) : group 1, tobramycin alone; group 2, tobramycin plus another antibiotic(s) not usually effective against P. aeruginosa; group 3, tobramycin plus another antibiotic(s), including carbenicillin in all instances. Group 2 contained cephalexin monohydrate, sodium cephalothin, chloramphenicol sodium succinate, clindamycin phosphate, ethambutol hydrochloride, isoniazid, potassium penicillin G, and tetracycline hydrochloride. Group 3 contained amphotericin B, disodium carbenicillin, sodium cephalothin, clindamycin phosphate, sodium methicillin, and tetracycline hydrochloride. Data on the susceptibility of the P. aeruginosa strains to these antibiotics were not available, with the exception that all strains from patients in group 3 were susceptible to carbenicillin. As indicated in Table 3 , group 1 included six courses of therapy; group 2, nine; and group 3, 14. One-half of group 1 patients were moderately ill, whereas the majority of group 2 and 3 patients were seriously or critically ill (79%; 100%). All groups received essentially the same mean tobramycin dosage, though the mean and median duration of therapy were longer for group 3. Eighty-three percent of the patients receiving tobramycin alone responded satisfactorily, compared to 57% of those given tobramycin and carbenicillin and only 22% of those in group 2.
Two patients (no. 1, 2) with Pseudomonas bone and/or cartilage infections were treated successfully. Patient 1 (vertebral osteomyeJlitis) responded satisfactorily to a 56-day course of tobramycin alone, whereas the addition of carbenicillin and resection of the infected tissue was necessary before patient 2 (osteomyelitis and costochondritis) became culture negative.
Seven patients (no. 3 to 9) received tobramycin for infection of the urinary tract. The results were satisfactory except for patients 8 and 9 . The former inadvertently received only two doses; the latter (patient 9) had received a renal transplant, still had her original kidneys, and was rejecting the transplant.
Two patients were treated for wound infection (no. 10, 11); one improved clinically and bacteriologically while on treatment; the other was very debilitated and eventually required re-operation for deep abdominal abscesses.
Six patients (including two with urinary tract infections) received tobramycin for respiratory tract infections (no. 6, 7, 12 to 15) . Two of these patients failed to improve clinically, one (no. 14) died after receiving only 4 days of therapy while the other (no. 15), comatose and requiring continuous mechanical respiratory assistance, showed no clinical improvement on antimicrobial therapy.
Nine patients were treated for 10 episodes of pseudomonas septicemia, usually following severe thermal bums. Although maintenance of life and suppression of infection could be considered satisfactory in these patients, by our previously sfated criteria of response, four of the episodes were considered to respond satisfactorily and six (60%) were unsatisfactory (one patient had one satisfactory and one unsatisfactory course of therapy). Four of five burn-associated septicemic patients who were therapeutic failures received tobramycin for 5 days or less; all five were in critical condition when tobramycin therapy was initiated.
Of 15 patients who had previously failed to improve with gentamicin alone (6 patients) or with carbenicillin (9 patients), six (40%) responded satisfactorily to tobramycin, either alone (2 patients) or with carbenicillin (4 patients). All four of the successful tobramycincarbenicillin treatment courses followed previously unsuccessful gentamicin-carbenicillin therapy.
No clinical evidence of toxicity was detected in the 25 patients and laboratory evidence of toxicity was noted in only 4 of 24 patients studied. These four were critically ill septicemic patients (no. 21 to 23, 25) who had an average rise of serum creatinine of 1.5 mg/100 ml terminally; all were hypotensive, were receiving multiple other medications, and had received tobramycin for only 1 to 3 days.
Despite prolonged courses of tobramycin (11 courses longer than 2 weeks; four courses longer than 7 weeks), no ototoxicity was found either clinically or by serial audiography.
DISCUSSION
Tobramycin has been shown to be effective in the treatment of urinary tract infection, septicemia, and pneumonia due to various gram-negative bacilli (8, 9, 18) . The evaluation of tobramycin in patients with P. aeruginosa VOL. 8, 1975 25 (4, 10) . Most gentamicin toxicity has been associated with serum levels of 8 to 12 ,ug/ml or higher (5, 17) . Since the pharmacokinetics and toxic characteristics of gentamicin and tobramycin are nearly alike, comparable serum levels of tobramycin might be expected to be toxic (15) . Tobramycin serum levels greater than 9.0 ,ug/ml were found only three times after intramuscular administration of the antibiotic. In one case, high serum levels (12.0, 13.5 ,ug/ml) were initially obtained in an azotemic patient (no. 6); adjustment of dosage brought serum levels below 8 ,ug/ml. The other two high serum concentrations (9.1 and 9.2 Ag.ml) occurred in patients 1 and 17 and were isolated events, possibly reflecting either variable absorption from the injection site, or variability intrinsic in the assay method. These data suggest that maintenance of serum levels below the 8-to 12-Ag/ml level is associated with a low incidence of toxicity. One can only speculate, however, whether a higher success rate could be achieved by maintaining higher (and more toxic) serum levels. We conclude that tobramycin can safely be used to treat serious P. aeruginosa infections. Treatment of seriously or critically ill patients was most successful when carbenicillin was used in conjunction with tobramycin. Although comparable data for gentamicin-treated tobramycin-failures are lacking, it should be noted that four of nine patients (44%) who previously received gentamicin and carbenicillin without improvement did respond satisfactorily to to-bramycin and carbenicillin therapy. Our data confirm the previously reported lower tobramycin MIC for Pseudomonas. The lower success in the 10 episodes of septicemia suggest that dosages of tobramycin possibly should be increased above those used in this study for life-threatening infections.
